I am a physician-scientist that focuses on translational laboratory-based cancer research with a particular emphasis on hematological malignancies and on cancer predisposition syndromes. Another major research interest is centrosomal biology and chromosomal aneuploidy and its roles in developmental biology and cancer. These two interests are merged in the study of leukemias associated with germline aneuploidy (Down Syndrome).
We combine advanced genomic approaches with functional pre-clinical models. Several of our discoveries proved to be of general importance to children and adults with acute leukemias. These include the discovery of ERG as an important hematopoietic oncogene, in addition to its known role in prostate cancer, and the discoveries of unique activating JAK2 mutations and of mutational activation of the cytokine receptors to TSLP and interleukin 7 in acute lymphoblastic leukemias (ALL).
These findings have led to new diagnostic tests and clinical trials of ALL in adult and children. Our more general cancer-aneuploidy and centrosomal biology research has been promoted by our discovery of STIL (previously named SIL), a gene disrupted in T-ALL, is a major centrosomal duplication factor in mammalian cells. We study how STIL, centrosomes and the hedgehog pathway are involved in development and cancer. We are developing novel therapeutics targeting the STIL pathways for epithelial cancers, for example ovarian cancer. This line of research reflects the integrative nature of current cancer research focusing on biological processes in addition to specific types of cancers.
Our research of Down Syndrome and of STIL (that is involved in autosomal recessive microcephaly) have led me to further develop my research interest in congenital and hereditary disorders predisposing to cancer. Germline variants are increasingly recognized as key players in cancer. We are currently studying human pedigrees and creating mouse models of such germline driven disorders. These studies have been funded by multiple national and international grants and have involved multiple national and international collaborations in both basic and clinical research with scientists and clinicians in North America, Australia, Japan and Europe.
1993, M.Ped., Molecular Biology, Pediatrics (Cum Laude), Tel Aviv University, Israel
1983, M.D., Medicine, Cum Laude, Hebrew University of Jerusalem
1996, National Cancer Institute, Bethesda, MD
1991, Research Fellow, Children's Cancer Research Institute, Vienna, Austria
1993, Pediatric Residency, Beilinson Medical Center, Petach Tikva, Israel
2018–Present, Research Professor, Department of Systems Biology, City of Hope Beckman Research Institute, Monrovia, CA
2016–2018, Head, The Tel-Aviv University Gene Development and Environment Pediatric Research Institute in Sheba Medical Center, Tel Hashomer, Israel
2015–Present, Head, Dotan Research Center for Hematological Malignancies, Tel Aviv University, Tel Aviv, Israel
2015–2018, Head, Research and Development, Edmond and Lily Safra Children’s Hospital, Sheba Medical Center Israel, Tel Hashomer, Israel
2010–2018, Director, MD-PhD program, Sackler Medical School, Tel Aviv University, Tel Aviv, Israel
2001–2018, Head, Functional Genomics and Leukemia Research Section, Sheba Medical Center, Tel Hashomer, Israel
2014–Present, The Shapiro Endowed Chair of Hematological Malignancies, Tel Aviv University, Tel Aviv, Israel
2012–Present, Full Professor, Sackler Medical School, Tel Aviv University, Tel Aviv, Israel
2007–2011, Associate Professor, Sackler Medical School, Tel Aviv University, Tel Aviv, Israel
2001–2007, Senior Lecturer, Sackler Medical School, Tel Aviv University, Tel Aviv, Israel
2000–Present, Senior Physician, Department of Pediatric Hemato-Oncology, Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Tel Hashomer, Israel
1998–2001, Adjunct Assistant Professor, John’s Hopkins Medical Faculty, Baltimore, MD
1994–2000, Postdoctoral Fellow, National Cancer Institute, Genetics Branch, Bethesda, MD
1984–1988, Military Physician, Head research section in the Medical Corps
Awards & Memberships
2022, EHA Mentorship and Education Award
2022, ICRF Professorship Award
2017, Honorary Knighthood awarded by the President of Italy for promoting the science and medicine of children with cancer between Israel and Italy
2014, The Inaugural Daniel Burton Visiting Professorship of Pediatric Malignancies SickKids Hospital Toronto, Canada
2012, 13th Annual Daniel Burton Lecture in Leukemia, SickKids Hospital Toronto
2011, The Swiss Bridge Award for research excellence in childhood cancer
2010, Haddow Visiting Professorship, Institute of Cancer Research, Sutton, London, UK
2008, Presidential Award – British Society of Heamatology Annual Scientific Meeting
2008, 2009, 2013, Moran Prize for Research Excellence in Pediatrics, Tel – Aviv University
2006, TEVA Inc Founder Award for Research Excellence
2006, Owen Rennert’s Endowed Lecture in Pediatric Oncology, Georgetown University
2002, 2006, Excellence Award, Israel Cancer Association
2002, Hannover Award for Leukemia and Lymphoma Research
1999, NIH Fellows Award for Research Excellence
Kratz, C. P. and S. Izraeli. "Down Syndrome, Rasopathies, and Other Rare Syndromes." Semin Hematol 54, no. 2 (Apr 2017): 123-28
Savino, A. M. and S. Izraeli. "Interleukin-7 Signaling as a Therapeutic Target in Acute Lymphoblastic Leukemia." Expert Rev Hematol 10, no. 3 (Mar 2017): 183-85.
Frishman-Levy, L. and S. Izraeli, Advances in understanding the pathogenesis of CNS acute lymphoblastic leukaemia and potential for therapy. Br J Haematol, 2017. 176(2): p. 157-167.
Ofran, Y. and S. Izraeli, BCR-ABL (Ph)-like acute leukemia-Pathogenesis, diagnosis and therapeutic options. Blood Rev, 2017. 31(2): p. 11-16
Izraeli, S., The acute lymphoblastic leukemia of Down Syndrome - Genetics and pathogenesis. Eur J Med Genet, 2016. 59(3): p. 158-61.
Savino, A.M. and S. Izraeli, On mice and humans: the role of thymic stromal lymphopoietin in human B-cell development and leukemia. Haematologica, 2016. 101(4): p. 391-3.
Pui, C.H., J.J. Yang, S.P. Hunger, R. Pieters, M. Schrappe, A. Biondi, A. Vora, A. Baruchel, L.B. Silverman, K. Schmiegelow, G. Escherich, K. Horibe, Y.C. Benoit, S. Izraeli, A.E. Yeoh, D.C. Liang, J.R. Downing, W.E. Evans, M.V. Relling, and C.G. Mullighan, Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol, 2015. 33(27): p. 2938-48.
Tal, N., C. Shochat, I. Geron, D. Bercovich, and S. Izraeli, Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia. Cell Mol Life Sci, 2014. 71(3): p. 365-78.
Roberts, I. and S. Izraeli, Haematopoietic development and leukaemia in Down syndrome. Br J Haematol, 2014. 10.1111/bjh.13096.
Mezei, G., M. Sudan, S. Izraeli, and L. Kheifets, Epidemiology of childhood leukemia in the presence and absence of Down syndrome. Cancer Epidemiol, 2014. 10.1016/j.canep.2014.07.006.
Izraeli, S., A. Vora, C.M. Zwaan, and J. Whitlock, How I treat ALL in Down's syndrome: pathobiology and management. Blood, 2014. 123(1): p. 35-40.
Izraeli, S., C. Shochat, N. Tal, and I. Geron, Towards precision medicine in childhood leukemia - Insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia. Cancer Lett, 2014. 10.1016/j.canlet.2014.02.009.
Izraeli, S., Beyond Philadelphia: 'Ph-like' B cell precursor acute lymphoblastic leukemias - diagnostic challenges and therapeutic promises. Curr Opin Hematol, 2014. 21(4): p. 289-96.
Birger, Y. and S. Izraeli, DYRK1A in Down syndrome: an oncogene or tumor suppressor? J Clin Invest, 2012. 122(3): p. 807-10.
Izraeli, S., Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside? Br J Haematol, 2010. 151(2): p. 119-31.
Bourquin, J.P. and S. Izraeli, Where can biology of childhood ALL be attacked by new compounds? Cancer Treat Rev, 2010. 36(4): p. 298-306.
Ganmore, I., G. Smooha, and S. Izraeli, Constitutional aneuploidy and cancer predisposition. Hum Mol Genet, 2009. 18(R1): p. R84-93.
Izraeli, S., L. Rainis, L. Hertzberg, G. Smooha, and Y. Birger, Trisomy of chromosome 21 in leukemogenesis. Blood Cells, Molecules, and Diseases, 2007. 39(2): p. 156-159.
Izraeli, S., Down's syndrome as a model of a pre-leukemic condition. Haematologica, 2006. 91(11): p. 1448-52.
Izraeli, S., Perspective: chromosomal aneuploidy in leukemia--lessons from down syndrome. Hematol Oncol, 2006. 24(1): p. 3-6.
Izraeli, S., Chromosome copy number and leukemia-lessons from Down's syndrome. Hematology, 2005. 10 Suppl 1: p. 164-6.
Somech, R., S. Izraeli, and J.S. A, Histone deacetylase inhibitors--a new tool to treat cancer. Cancer Treat Rev, 2004. 30(5): p. 461-72.
Izraeli, S. and D. Waldman, Minimal residual disease in childhood acute lymphoblastic leukemia: current status and challenges. Acta Haematol, 2004. 112(1-2): p. 34-9.
Izraeli, S., Leukaemia -- a developmental perspective. Br J Haematol, 2004. 126(1): p. 3-10.
Izraeli, S., Congenital syndromes and leukemia: clues to pathogenesis. Rev Clin Exp Hematol, 2003. 7(3): p. 246-60.
Izraeli, S., I. Witz, and M. Micksche, Cancer research--from bench to bedside. Isr Med Assoc J, 2002. 4(9): p. 746-8.
Izraeli, S. and G. Rechavi, Molecular medicine--an overview. Isr Med Assoc J, 2002. 4(8): p. 638-40.
Izraeli, S., A. Rachmel, and M. Nitzan, [Vestibular dysfunction and deafness complicating mumps parotitis]. Harefuah, 1989. 117(9): p. 243-4.
Izraeli, S., A. Israeli, and Y. Danon, [Pharmacological treatment of cyanide poisoning]. Harefuah, 1988. 114(7): p. 338-42.